Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function

Journal of Cystic Fibrosis

Volumn 15, Issue 5, 2016, Pages 681-688

  Hunt, William R ^a,b,c   Helfman, Beth R ^a,b,c   McCarty, Nael A ^a,b,c   Hansen, Jason M ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^d BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Advanced glycation end products; Cystic fibrosis; Cystic fibrosis related diabetes; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CALGRANULIN C; HEMOGLOBIN A1C; HIGH MOBILITY GROUP B1 PROTEIN; LIGAND; ADVANCED GLYCATION END PRODUCT RECEPTOR;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; LUNG FUNCTION; LUNG FUNCTION TEST; PROTEIN BLOOD LEVEL; ADOLESCENT; BLOOD; FEMALE; MALE; PATHOPHYSIOLOGY; PATIENT ACUITY; PROCEDURES; REGISTER; STATISTICS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADOLESCENT; ADULT; CYSTIC FIBROSIS; DIABETES MELLITUS; FEMALE; FORCED EXPIRATORY VOLUME; GLYCATION END PRODUCTS, ADVANCED; HUMANS; MALE; PATIENT ACUITY; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; REGISTRIES; RESPIRATORY FUNCTION TESTS; S100A12 PROTEIN; STATISTICS AS TOPIC; UNITED STATES;

EID: 84955292969     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.12.011     Document Type: Article

References (46)

1. [1] Bakker, S.F., Tushuizen, M.E., Gozutok, E., et al. Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease. Nutr Metab Cardiovasc Dis 25:2 (2015), 230–235.
2. [2] Barrett, T., Troup, D.B., Wilhite, S.E., et al. NCBI GEO: mining tens of millions of expression profiles–database and tools update. Nucleic Acids Res 35:Database issue (2007), D760–D765.
3. [3] Blackwell, T.S., Stecenko, A.A., Christman, J.W., Dysregulated NF-kappaB activation in cystic fibrosis: evidence for a primary inflammatory disorder. Am J Physiol Lung Cell Mol Physiol 281:1 (2001), L69–L70.
4. [4] Brett, J., Schmidt, A.M., Yan, S.D., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:6 (1993), 1699–1712.
5. [5] CFF, Cystic Fibrosis Foundation Patient Registry Annual Data Report. 2013, CF Foundation, Bethesda, MD.
6. [6] Chavakis, T., Bierhaus, A., Al-Fakhri, N., et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198:10 (2003), 1507–1515.
7. [7] Christaki, E., Opal, S.M., Keith, J.C. Jr., et al. A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia. Shock 35:5 (2011), 492–498.
8. [8] Coughlan, M.T., Thorburn, D.R., Penfold, S.A., et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20:4 (2009), 742–752.
9. [9] de la Maza, M.P., Uribarri, J., Olivares, D., et al. Weight increase is associated with skeletal muscle immunostaining for advanced glycation end products, receptor for advanced glycation end products, and oxidation injury. Rejuvenation Res 11:6 (2008), 1041–1048.
10. [10] Demling, N., Ehrhardt, C., Kasper, M., Laue, M., Knels, L., Rieber, E.P., Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res 323:3 (2006), 475–488.
11. [11] Entezari, M., Weiss, D.J., Sitapara, R., et al. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol Med 18:1 (2012), 477–485.
12. [12] Flume, P.A., Mogayzel, P.J. Jr., Robinson, K.A., Rosenblatt, R.L., Quittell, L., Marshall, B.C., Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 182:3 (2010), 298–306.
13. [13] Foell, D., Seeliger, S., Vogl, T., et al. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 58:7 (2003), 613–617.
14. [14] Gao, L., Kim, K.J., Yankaskas, J.R., Forman, H.J., Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol 277:1 Pt 1 (1999), L113–L118.
15. [15] Goova, M.T., Li, J., Kislinger, T., et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 159:2 (2001), 513–525.
16. [16] Hofmann, M.A., Drury, S., Fu, C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:7 (1999), 889–901.
17. [17] Hori, O., Brett, J., Slattery, T., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270:43 (1995), 25752–25761.
18. [18] Hunt, W.R., Zughaier, S.M., Guentert, D.E., et al. Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol Lung Cell Mol Physiol 306:1 (2014), L43–L49.
19. [19] Iannitti, R.G., Casagrande, A., De Luca, A., et al. Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis. Am J Respir Crit Care Med 188:11 (2013), 1338–1350.
20. [20] Ishihara, K., Tsutsumi, K., Kawane, S., Nakajima, M., Kasaoka, T., The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 550:1–3 (2003), 107–113.
21. [21] Kerkeni, M., Saidi, A., Bouzidi, H., Ben Yahya, S., Hammami, M., Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy. Microvasc Res 84:3 (2012), 378–383.
22. [22] Khan, T.Z., Wagener, J.S., Bost, T., Martinez, J., Accurso, F.J., Riches, D.W., Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151:4 (1995), 1075–1082.
23. [23] Koch, C., Rainisio, M., Madessani, U., et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European epidemiologic registry of cystic fibrosis. Pediatr Pulmonol 32:5 (2001), 343–350.
24. [24] Lanng, S., Thorsteinsson, B., Pociot, F., et al. Diabetes mellitus in cystic fibrosis: genetic and immunological markers. Acta Paediatr 82:2 (1993), 150–154.
25. [25] Lewis, C., Blackman, S.M., Nelson, A., et al. Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med 191:2 (2015), 194–200.
26. [26] Lutterloh, E.C., Opal, S.M., Pittman, D.D., et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care, 11(6), 2007, R122.
27. [27] Makam, M., Diaz, D., Laval, J., et al. Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proc Natl Acad Sci U S A 106:14 (2009), 5779–5783.
28. [28] Malherbe, P., Richards, J.G., Gaillard, H., et al. CDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 71:2 (1999), 159–170.
29. [29] Marshall, B.C., Butler, S.M., Stoddard, M., Moran, A.M., Liou, T.G., Morgan, W.J., Epidemiology of cystic fibrosis-related diabetes. J Pediatr 146:5 (2005), 681–687.
30. [30] Mulrennan, S., Baltic, S., Aggarwal, S., et al. The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes. Sci Rep, 5, 2015, 8931.
31. [31] Nakamura, K., Yamagishi, S., Adachi, H., et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 24:2 (2008), 109–114.
32. [32] Neeper, M., Schmidt, A.M., Brett, J., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:21 (1992), 14998–15004.
33. [33] O'Sullivan, B.P., Freedman, S.D., Cystic fibrosis. Lancet 373:9678 (2009), 1891–1904.
34. [34] Rowe, S.M., Jackson, P.L., Liu, G., et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 178:8 (2008), 822–831.
35. [35] Schmidt, A.M., Vianna, M., Gerlach, M., et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267:21 (1992), 14987–14997.
36. [36] Soro-Paavonen, A., Watson, A.M., Li, J., et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57:9 (2008), 2461–2469.
37. [37] Soulis, T., Thallas, V., Youssef, S., et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40:6 (1997), 619–628.
38. [38] Stecenko, A.A., Moran, A., Update on cystic fibrosis-related diabetes. Curr Opin Pulm Med 16:6 (2010), 611–615.
39. [39] Taguchi, A., Blood, D.C., del Toro, G., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405:6784 (2000), 354–360.
40. [40] Tirouvanziam, R., de Bentzmann, S., Hubeau, C., et al. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 23:2 (2000), 121–127.
41. [41] van Zoelen, M.A., Schouten, M., de Vos, A.F., et al. The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 182:7 (2009), 4349–4356.
42. [42] van Zoelen, M.A., van der Sluijs, K.F., Achouiti, A., et al. Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 391:2 (2009), 265–273.
43. [43] Vogl, T., Propper, C., Hartmann, M., et al. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem 274:36 (1999), 25291–25296.
44. [44] White, H., Pollard, K., Etherington, C., et al. Nutritional decline in cystic fibrosis related diabetes: the effect of intensive nutritional intervention. J Cyst Fibros 8:3 (2009), 179–185.
45. [45] Xie, J., Mendez, J.D., Mendez-Valenzuela, V., Aguilar-Hernandez, M.M., Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal 25:11 (2013), 2185–2197.
46. [46] Yan, S.D., Chen, X., Fu, J., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:6593 (1996), 685–691.